Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab + Certolizumab in Rheumatoid Arthritis
2023-504045-31-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab, certolizumab pegol, methotrexate, 5-aminosalicylic acid + sulphasalazine, chloroquine and 2 more in rheumatoid arthritis (RA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Started Oct 2023; status: completed.
02
Drugs
nipocalimabcertolizumab pegolmethotrexate5-aminosalicylic acid + sulphasalazinechloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-504045-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504045-31-00.